Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Olanzapine as First Line Treatment for Prevention of Nausea and Vomiting Induced by Chemotherapy of Lung Cancer: a Multicenter, Double-blind and Randomized Trial

NCT03571126 is registered in ClinicalTrials.gov with Zunyi Medical College as lead sponsor.

NCT NCT03571126
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03571126 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Olanzapine as First Line Treatment for Prevention of Nausea and Vomiting Induced by Chemotherapy of Lung Cancer: a Multicenter, Double-blind and Randomized Trial
Lead sponsor
Zunyi Medical College
Phase
Phase 4
Overall status
Unknown status
Start date
May 9, 2019
Completion date
August 1, 2023
Enrollment
156 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy-induced nausea and vomiting, lung cancer